University Of Maryland, School Of Medicine is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
The University of Maryland School of Medicine (UMSOM) is one of the oldest public medical schools in the United States. The Department of Neurology and the MARC (Medical Academy for Research in Cognition) conduct extensive neurodegeneration research, with particular strengths in Alzheimer's disease, Parkinson's disease, and traumatic brain injury.
The Center for Alzheimer's Disease focuses on:
The MARC is an NIH-funded research center:
Alzheimer's Disease:
Parkinson's Disease:
Traumatic Brain Injury:
The MARC is an NIH-funded research center with multiple research cores:
Research Cores:
Research Areas:
University of Maryland researchers have contributed to:
The Center for Alzheimer's Disease focuses on:
Clinical Research:
Basic Science:
Community Outreach:
The University of Maryland has established a unique program focusing on TBI and its long-term consequences:
Research Areas:
Clinical Services:
Key Findings:
The University of Maryland School of Medicine offers several training programs relevant to neurodegenerative diseases:
The school maintains active collaborations with:
These partnerships facilitate joint research projects, student exchanges, and international clinical trials.
| Condition | Focus | Phase | Status |
|---|---|---|---|
| Alzheimer's disease | Anti-amyloid antibody | Phase 3 | Recruiting |
| Alzheimer's disease | Tau aggregation inhibitor | Phase 2 | Ongoing |
| Parkinson's disease | Neuroprotective agent | Phase 2 | Active |
| TBI | Rehabilitation device | Phase 2 | Recruiting |
| CTE | Biomarker development | Observational | Ongoing |
The University of Maryland's neurodegenerative disease research priorities include:
The University of Maryland School of Medicine has established itself as a leading institution for neurodegenerative disease research, with particular strengths in traumatic brain injury and chronic traumatic encephalopathy. The Maryland Alzheimer's Disease Research Center (MARC) provides a comprehensive platform for Alzheimer's disease research, while the TBI and CTE program addresses a critical gap in understanding the long-term consequences of brain injury.
Through its commitment to basic science research, clinical trials, and community outreach, the University of Maryland continues to make significant contributions to understanding and treating neurodegenerative diseases.
Blennow K, et al. CSF biomarkers in Alzheimer's disease. Nature Reviews Neurology. 2016. ↩︎
Zetterberg H, et al. Blood biomarkers for Alzheimer's disease. Molecular Psychiatry. 2019. ↩︎
Trojanowski JQ, Lee VM. The alpha-synucleinopathies. Annals of Neurology. 2003. ↩︎
McKee AC, et al. Chronic traumatic encephalopathy in athletes. Acta Neuropathologica. 2013. ↩︎ ↩︎ ↩︎
Stein TD, et al. Neurodegeneration in chronic traumatic encephalopathy. Brain Pathology. 2015. ↩︎ ↩︎
Corson K, et al. Post-acute rehabilitation after TBI. Archives of Physical Medicine and Rehabilitation. 2022. ↩︎
Ghajar J. Traumatic brain injury: beyond the threshold. Neurosurgery. 2000. ↩︎
Relkin N, et al. Novel CSF biomarkers for Alzheimer's disease. Alzheimer's & Dementia. 2019. ↩︎
Gavett BE, et al. Chronic traumatic encephalopathy neuropathology. Journal of Neuropathology & Experimental Neurology. 2011. ↩︎
Chen X, et al. Microglial activation in neurodegenerative disease. Journal of Neuroinflammation. 2020. ↩︎
Randazzo J, et al. Tau pathology in former NFL players. JAMA Neurology. 2023. ↩︎
Wilson L, et al. Chronic outcomes of TBI. Nature Reviews Neurology. 2022. ↩︎